Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Oct 14;14(1):177.
doi: 10.1038/s41408-024-01154-z.

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO's pharmacovigilance database

Pierre-Marie Morice  1   2 , Sabine Khalife-Hachem  3 , Marion Sassier  4 , Véronique Lelong-Boulouard  4   5 , Alina Danu  3 , Florence Pasquier  3   6 , Aline Renneville  6   7 , Charles Dolladille  8   9 , Jean-Baptiste Micol  3   6   7
Affiliations
Meta-Analysis

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO's pharmacovigilance database

Pierre-Marie Morice et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. MICOL reports personal fees from Jazz Pharmaceuticals, from Astellas Pharma, from Servier, from AbbVie, from Gilead Sciences, from AstraZeneca, outside the submitted work. All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Risk and incidence of therapy-associated acute lymphoblastic leukemias in randomized controlled trials.
Risk of t-ALL (A) with lenalidomide versus control in 18 RCTs. Events refers to the number of patients with acute lymphoblastic leukemia in regard to the total number of patients (intent-to-treat). Incidence of ALL (B) with lenalidomide treatment per 100 patients in 18 RCTs. CI Confidence Intervals, RCTs Randomized Controlled Trials, SCT Stem-Cell Transplantation, OR Odds Ratio.
See this image and copyright information in PMC

References

    1. Jones JR, Cairns DA, Menzies T, Pawlyn C, Davies FE, Sigsworth R, et al. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. EClinicalMedicine. 2023;62:102099. - PMC - PubMed
    1. Holstein SA, Jung S-H, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4:e431–42. - PMC - PubMed
    1. Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. - PubMed
    1. Morton S, Murad M, O’Connor E, Lee C, Booth M, Vandermeer B et al. Quantitative Synthesis—An Update - Methods Guide for Effectiveness and Comparative Effectiveness Reviews - NCBI Bookshelf. 2018. https://www.ncbi.nlm.nih.gov/books/NBK519365/ (accessed 18 Mar2020).
    1. Faillie J-L, Ferrer P, Gouverneur A, Driot D, Berkemeyer S, Vidal X, et al. A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events. J Clin Epidemiol. 2017;86:168–75. - PubMed

MeSH terms

LinkOut - more resources